We are live on !
Find out more
Stonepine Capital Management Portfolio holdings
AUM
$177M
Turnover
41.12%
1-Year Est. Return
91.13%
This Fund
S&P 500
This Quarter Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
-$72.5M
(-29%)
Cap. Flow
+$12.6M
Cap. Flow % of AUM
Cap. Flow %
7.11%
Top 10 Holdings %
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.7
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eloxx Pharmaceuticals
ELOX
|
+$5.07M |
| 2 |
Edesa Biotech
EDSA
|
+$3.85M |
| 3 |
Indivior Pharmaceuticals
INDV
|
+$3.63M |
| 4 |
Cabaletta Bio
CABA
|
+$2.85M |
| 5 |
Satellos Bioscience
MSLE
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenax Therapeutics
TENX
|
+$4.03M |
| 2 |
Zevra Therapeutics
ZVRA
|
+$2.46M |
| 3 |
Xoma
XOMA
|
+$2.18M |
| 4 |
Abeona Therapeutics
ABEO
|
+$1.04M |
| 5 |
Inhibikase Therapeutics
IKT
|
+$1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.11% |
| 2 | Miscellaneous | 25.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
51
Inhibikase Therapeutics
IKT
$216M
| $804K | 0.45% |
396,179
-561,023
| -59% | -$1M |
2024 Q4
6 quarters
|
|
52
Zentalis Pharmaceuticals
ZNTL
$186M
| $784K | 0.44% |
161,583
-107,517
| -40% | -$429K |
2025 Q1
5 quarters
|
|
53
CytomX Therapeutics
CTMX
$510M
| $769K | 0.43% |
205,000
+5,000
| +3% | +$19.1K |
2026 Q1
1 quarter
|
|
54
CALL
MannKind Corp
MNKD
$1.13B
| $750K | 0.42% |
250,000
-250,000
| -50% | -$812K |
2026 Q1
1 quarter
|
|
55
Nuvectis Pharma
NVCT
$603M
| $736K | 0.42% |
+40,000
| New | +$448K |
2026 Q2
0 quarters
|
|
56
Crescent Biopharma
CBIO
$501M
| $720K | 0.41% |
40,000
-45,000
| -53% | -$879K |
2025 Q4
2 quarters
|
|
57
PMV Pharmaceuticals
PMVP
$70M
| $718K | 0.41% |
536,086
-172,016
| -24% | -$221K |
2024 Q4
6 quarters
|
|
58
Oruka Therapeutics
ORKA
$6.41B
| $714K | 0.4% |
+7,500
| New | +$500K |
2026 Q2
0 quarters
|
|
59
Radiopharm Theranostics
RADX
$17M
| $670K | 0.38% |
51,000,000
| – | – |
2025 Q4
2 quarters
|
|
60
OnKure Therapeutics
OKUR
$106M
| $596K | 0.34% |
130,684
-1,894
| -1% | -$8.13K |
2026 Q1
1 quarter
|
|
61
NervGen Pharma
NGEN
$147M
| $560K | 0.32% |
+271,678
| New | +$843K |
2026 Q2
0 quarters
|
|
62
CalciMedica
CALC
$10M
| $545K | 0.31% |
+124,486
| New | +$441K |
2026 Q2
0 quarters
|
|
63
Arvinas
ARVN
$514M
| $499K | 0.28% |
60,000
+32,500
| +118% | +$303K |
2026 Q1
1 quarter
|
|
64
BioAge Labs
BIOA
$269M
| $490K | 0.28% |
20,000
-30,000
| -60% | -$542K |
2025 Q1
5 quarters
|
|
65
Opus Genetics
IRD
$305M
| $414K | 0.23% |
100,718
+32,030
| +47% | +$149K |
2026 Q1
1 quarter
|
|
66
QT Imaging Holdings
QTI
$31.3M
| $407K | 0.23% |
+100,000
| New | +$556K |
2026 Q2
0 quarters
|
|
67
Boundless Bio
BOLD
$57.1M
| $386K | 0.22% |
154,595
-443,087
| -74% | -$682K |
2025 Q2
4 quarters
|
|
68
SiNtx Technologies
SINT
$12.8M
| $333K | 0.19% |
+209,205
| New | +$485K |
2026 Q2
0 quarters
|
|
69
Cellectar Biosciences
CLRB
$11.4M
| $291K | 0.16% |
+104,550
| New | +$292K |
2026 Q2
0 quarters
|
|
70
Eupraxia Pharmaceuticals
EPRX
$451M
| $287K | 0.16% |
+43,491
| New | +$300K |
2026 Q2
0 quarters
|
|
71
SAB Biotherapeutics
SABS
$305M
| $286K | 0.16% |
73,271
+23,271
| +47% | +$86.6K |
2026 Q1
1 quarter
|
|
72
Adlai Nortye Group ADS
ANL
$615M
| $279K | 0.16% |
+24,257
| New | +$295K |
2026 Q2
0 quarters
|
|
73
Senseonics Holdings Inc
SENS
$503M
| $277K | 0.16% |
+48,680
| New | +$312K |
2026 Q2
0 quarters
|
|
74
Pliant Therapeutics
PLRX
$53.2M
| $263K | 0.15% |
230,538
+5,888
| +3% | +$7.17K |
2025 Q3
3 quarters
|
|
75
Codexis
CDXS
$130M
| $248K | 0.14% |
109,662
-308,332
| -74% | -$768K |
2025 Q3
3 quarters
|
|
Similar funds
CMP
ALAM
IAMH
Stonepine Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.
- Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
- Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
- Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
- Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
- Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
- Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
- Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.
Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.